Pro PSA:: a "pro cancer" form of PSA?

被引:13
|
作者
Peyromaure, M
Fulla, Y
Debré, B
Dinh-Xuan, AT
机构
[1] Cochin Hosp, Dept Urol, F-75014 Paris, France
[2] Cochin Hosp, Dept Nucl Med, Paris, France
[3] Cochin Hosp, Physiol Lab, Paris, France
关键词
D O I
10.1016/j.mehy.2004.06.006
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Pro PSA, the precursor of PSA, is an inactive 244-amino acid protein secreted by prostatic cells. Pro PSA, a distinct molecular form of free PSA in serum, includes native as well as several truncated forms. Clinical studies have recently provided evidence that pro PSA is associated with prostate cancer (PCa). The truncated (-2) pro PSA form accounts for only 6-19% of free PSA in the serum of patients without PCa, but it represents up to 25-95% of free PSA in that of PCa patients. In the PSA range of 2-10 ng/ml, it has been suggested that pro PSA may be useful to detect PCa, and to spare 10-20% of unnecessary prostate biopsies. However, only scant information about the role of pro PSA is available to date, and its real impact on PCa detection remains to be determined. Furthermore, it is questionnable whether pro PSA could be predictive of tumor recurrence of PCa after therapy. Prospective clinical studies with long term followup are needed to clarify this point. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:92 / 95
页数:4
相关论文
共 50 条
  • [31] Association of Obesity and Smoking With PSA and PSA Velocity in Men With Prostate Cancer
    Algotar, Amit M.
    Stratton, Steven P.
    Ranger-Moore, James
    Stratton, M. Suzanne
    Hsu, C. H.
    Ahmann, Frederick R.
    Nagle, Raymond B.
    Thompson, Patricia A.
    AMERICAN JOURNAL OF MENS HEALTH, 2011, 5 (03) : 272 - 278
  • [32] To PSA or not to PSA? Still a question for men with a family history of prostate cancer
    Selkirk, Christina G.
    Helfand, Brian T.
    BJU INTERNATIONAL, 2016, 117 (04) : 545 - 545
  • [33] COMPARISON OF CONVENTIONAL PSA AND NANOTECHNOLOGY PSA IN INDIVIDUAL PROSTATE CANCER PATIENTS
    Alphs, Hannah
    O'Brien, Daniel C.
    Kan, Donghui
    Le, Brian V.
    Kim, Dae Y.
    Zhao, Lee C.
    Loeb, Stacy
    Smith, Norm D.
    Mirkin, Chad A.
    Thaxton, C. Shad
    Cooper, Phillip R.
    Catalona, William J.
    JOURNAL OF UROLOGY, 2010, 183 (04): : E44 - E44
  • [34] A significant correlation between PSA and PSA velocity in men with prostate cancer
    Nature Clinical Practice Urology, 2007, 4 (7): : 353 - 354
  • [35] Detection of prostate cancer in 2007 -: Part 1:: PSA and PSA kinetics
    Schroder, Fritz H.
    Carter, H. Ballentine
    Wolters, Tineke
    van den Bergh, Roderick C. N.
    Gosselaar, Claartje
    Bangma, Chris H.
    Roobol, Monique J.
    EUROPEAN UROLOGY, 2008, 53 (03) : 468 - 477
  • [36] Cost-benefit analysis of total PSA, free/total PSA and complexed PSA for prostate cancer screening
    Ellison, L
    Bright, S
    Veltri, R
    Cheli, C
    Partin, A
    JOURNAL OF UROLOGY, 2002, 167 (04): : 11 - 12
  • [38] Intraindividual variation of PSA, free PSA and complexed PSA in a cohort of patients with prostate cancer managed with watchful observation
    Bunting, PS
    DeBoer, G
    Choo, R
    Danjoux, C
    Klotz, L
    Fleshner, N
    CLINICAL BIOCHEMISTRY, 2002, 35 (06) : 471 - 475
  • [39] The clinical utility of measuring total PSA, PSA density, γ-seminoprotein and γ-seminoprotein/total PSA in prostate cancer prediction
    Sasaki, R
    Habuchi, T
    Sato, K
    Akao, T
    Kakinuma, H
    Zhang, LQ
    Wang, LZ
    Matsuo, S
    Sasaki, S
    Ogawa, O
    Kato, T
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2000, 30 (08) : 337 - 342
  • [40] Correlation between the Complex PSA/total PSA Ratio and the Free PSA/total PSA Ratio, Sensitivity and Specificity of Both Markers for the Diagnosis of Prostate Cancer
    Perez-Lanzac-Lorca, A.
    Barco-Sanchez, A.
    Romero, E.
    Martinez-Peinado, A.
    Lopez-Elorza, F.
    Sanchez-Sanchez, E.
    Alvarez-Ossorio-Fernandez, J. L.
    Castineiras-Fernandez, J.
    ACTAS UROLOGICAS ESPANOLAS, 2013, 37 (08): : 498 - 503